MJA
The Medical Journal of Australia

Supporting Information

Supplementary methods and results

This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.

Appendix to: Deng L, Glover C, Dymock M, et al. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. *Med J Aust* 2022; doi: 10.5694/mja2.51619.

1. Questions in day 3 and day 8 surveys

Survey section	Question	Response options
Any adverse event	Did you have any reactions following your most recent COVID-19 vaccination?	1. Yes 0. No
Medical advice/care sought	Did any of the symptoms cause you to seek advice/care from a doctor/healthcare professional?	1. Yes 0. No
	If yes, please select the type of advice/care that you sought	1, Phone advice (e.g. HealthDirect) 2, Care from a GP or Aboriginal Healthcare Worker (in person, telehealth, email, urgent care clinic, home visit) 3, Visit to a hospital emergency department
Solicited reactions	Please select all the reactions that you experienced:	
	Local reaction (pain, redness, swelling, itching at or near the injection site)	1. Yes 0. No
	Please select all that apply	1, Pain 2, Redness 3, Swelling 4, Itching
	Please indicate location of rash (select all that apply)	1, Face 2, Body 3, Arms 4, Legs
	Fever	1. Yes 0. No
	Please indicate location of rash (select all that apply)	1, Face 2, Body 3, Arms 4, Legs
	Rash (not at injection site)	1. Yes 0. No
	Please indicate location of rash (select all that apply)	1, Face 2, Body 3, Arms 4, Legs
	Did you experience any of the following symptoms at the same time as the rash?	1, Cough 2, Shortness of breath 3, Noisy or difficult breathing 4, Lip or tongue swelling 0, None of these
	When did the rash after vaccination start?	1, Within 1 hour after vaccination 2, 1 to 6 hours 3, 7 to 72 hours 4, More than 72 hours (3 days)
	How long did the rash last?	1, Less than 30 minutes 2, 30 minutes to 24 hours 3, More than 24 hours
	Chills (shivering and feeling cold)	1. Yes 0. No
	Headache, muscle/body aches, or joint aches/pain	1. Yes 0. No
	Please select all that apply	1, Headache 2, Muscle/body aches 3, Joint aches/pain

Survey section	Question	Response options
	Gastrointestinal symptoms	1. Yes 0. No
	Please select all that apply	1, Nausea 2, Vomiting 3, Diarrhoea 4, Abdominal pain
	Fatigue or tiredness	1. Yes 0. No
	Fainting/loss of consciousness	1. Yes 0. No
	Did you experience any of the following symptoms around the same time as the faint? (select all that apply)	1, Cough 2, Shortness of breath 3, Noisy or difficult breathing 4, Lip or tongue swelling 0, None of these
	When did the fainting/loss of consciousness after vaccination start?	1, Less than 5 minutes after vaccination 2, 5 to 30 minutes 3, More than 30 minutes
	How long did the fainting/loss of consciousness last?	1, Less than 1 minute 2, 1 to 5 minutes 3, More than 5 minutes
	Seizure	1. Yes 0. No
	When did the seizure after vaccination start?	1, Less than 30 minutes after vaccination 2, Same day 3, Next day 4, 2 or more days after vaccination
	How long did the seizure last?	1, Less than 1 minute 2, 1 to 5 minutes 3, 6 to 15 minutes 4, 16 to 30 minutes 5, More than 30 minutes
	Did you experience any other symptoms not listed above?	1. Yes 0. No
	Please specify	Free text
Symptom management	Did you take pain or fever medicine (e.g. paracetamol or ibuprofen) *at the time of* vaccination?	1. Yes 0. No
	Did you use something *after* vaccination to help your symptoms?	1. Yes 0. No
	Please check all that apply	1, Pain/fever relief (e.g. paracetamol or ibuprofen) 2, On skin (e.g. cream, icepack) 3, Anti-allergy medicine (e.g. antihistamine) 4, Other
Symptom resolution	Are you still experiencing any of the symptoms you reported?	0, No, all of my symptoms have gone 1, Yes, I am still experiencing one or more symptoms
Health impact	Did any of the symptoms you reported cause you to miss work, study or normal daily activities?	1. Yes 0. No
	How many days did you miss?	1, Less than 1 day 2, 1 day 3, 2 days 4, 3 or more days

Survey section	Question	Response options
Anaphylaxis history	Do you have a history of anaphylaxis or carry an EpiPen?	1. Yes 0. No
	What was the trigger?	1, Food 2, Medicine 3, Vaccine 4, Insect venom 5, Other
Underlying medical conditions	Do you have any chronic medical conditions?	1. Yes 0. No
	Please select all that apply	A, Heart disease (coronary heart disease or failure) B, Poorly controlled blood pressure C, Diabetes/Sugar D, Chronic lung disease (not including mild/moderate asthma) E, Obesity with BMI ≥40 kg/m2 F, Chronic kidney failure G, Chronic liver disease H, Cancer (not including blood or bone marrow cancer) diagnosed in the last 12 months I, Blood cancer (e.g. leukaemia, lymphoma or myelodysplastic syndrome) diagnosed within the last 5 years J, Currently receiving chemotherapy or radiotherapy K, Organ transplant recipient on immune suppressive therapy L, Bone marrow transplant recipient in the last 2 years M, Neurological condition (e.g. stroke, dementia) N, Chronic inflammatory conditions (e.g. rheumatoid arthritis, lupus) O, Primary or acquired immunodeficiency (including HIV) P, Other

2. Bayesian logistic regression model

Bayesian logistic regression models were used to model the proportion of participants reporting any AEFI in the Day 3 survey. A separate model was applied for each brand-dose combination, where y_g and n_g are the number of participants reporting any AEFI in the Day 3 survey and the total number of responses in the Day 3 survey, respectively, belonging to covariate group $g = 1,2,\dots,G$. Here, covariate group g is defined as the g^{th} unique combination of the covariates age (decade group), sex, Indigenous status, clinic type, jurisdiction and underlying medical conditions including anaphylaxis history (i.e., participants are separated into unique groups defined by the combination of their covariates). Denote $\boldsymbol{X}$ as the $G \times Q$ design matrix where the g^{th} row $(\boldsymbol{x}_g)$ is the unique combination of covariates (as defined above) and Q is the total number of model parameters required to represent the 6 categorical covariates. The proportion of participants belonging to covariate group g reporting any AEFI in the Day 3 survey (p_g) is modelled as:

$$y_g \sim \text{Binomial}(n_g, p_g)$$

$$\text{logit}(p_g) = \alpha + \boldsymbol{x}_g\boldsymbol{\beta}$$

Here, α is the intercept parameter and is interpreted as the log-odds of a participant reporting any AEFI in the Day 3 survey with all reference category covariate levels (i.e., 20-29 years old, male, non-Indigenous, general practice opt-out site, New South Wales jurisdiction, no history of anaphylaxis and no underlying medical conditions). The parameter vector $\boldsymbol{\beta} = (\beta_1, \beta_2, \dots, \beta_Q)$ contains the adjusted odds ratios for each covariate level. For example, β_1 is interpreted as the odds ratio of a <20 year old participant reporting any AEFI in the Day 3 survey compared to a 20-29 year old participant (the reference category) **adjusted** for sex, indigenous status, site type, jurisdiction and underlying medical condition. The following weakly informative priors were implemented on the model parameters:

$$\alpha \sim \text{Normal}(0, 2^2)$$

$$\beta_. \sim \text{Normal}(0, 2^2)$$

All statistical analyses and modelling were conducted using R version 4.1.0 and posterior distributions for model parameters were estimated via RStan.[1] Each model was run with 8 chains, each with 4,000 iterations and model convergence was assessed using RStan Hamiltonian Monte Carlo diagnostics.

1 RStan: the R interface to Stan [computer program]. Version R package version 2.282021. https://mc-stan.org/rstan/reference/rstan.html

Table 1. Demographic characteristics of responders and non-responders to the AusVaxSafety COVID-19 day 3 vaccine safety survey, 22 February – 30 August 2021, by vaccine and dose number

	Comirnaty				Vaxzevria			
	Dose 1 (2 374 982 enrolled)		Dose 2 (1 529 795 enrolled)		Dose 1 (566 548 enrolled)		Dose 2 (380 155 enrolled)	
Characteristic*	Non-responders	Responders	Non-responders	Responders	Non-responders	Responders	Non-responders	Responders
Number of people	1 028 674	1 346 308	576 091	953 704	133 121	433 427	77 611	302 544
Sex								
Men	218 844 (50.0%)	565 158 (42.0%)	136 696 (48.1%)	399 392 (42.0%)	52 911 (53.6%)	199 643 (46.4%)	32 989 (50.5%)	136 689 (45.5%)
Women	217 928 (49.8%)	777 187 (57.8%)	147 299 (51.8%)	551 535 (57.9%)	45 723 (46.3%)	230 019 (53.5%)	32 301 (49.4%)	163 831 (54.5%)
Other	758 (0.17%)	1 700 (0.13%)	356 (0.13%)	1 021 (0.11%)	143 (0.14%)	285 (0.07%)	48 (0.07%)	92 (0.03%)
Missing data	591 144	2 263	291 740	1 756	34 344	3 480	12 273	1 932
Age (years), median (IQR)	37 (27–46)	42 (33–49)	42 (32–48)	44 (37–49)	58 (37–67)	61 (52–68)	58 (50–66)	62 (54–70)
Age group (years)								
16–19†	64 213 (6.2%)	53 457 (4.0%)	13 593 (2.4%)	12 039 (1.3%)	2065 (1.6%)	2835 (0.65%)	163 (0.21%)	259 (0.09%)
20–29	252 714 (24.6%)	187 231 (13.9%)	104 080 (18.1%)	101 177 (10.6%)	17 876 (13.4%)	27 402 (6.3%)	6275 (8.1%)	9212 (3.0%)
30–39	266 465 (25.9%)	317 446 (23.6%)	122 597 (21.3%)	182 157 (19.1%)	16 891 (12.7%)	32 078 (7.4%)	6133 (7.9%)	12 995 (4.3%)
40–49	267 269 (26.0%)	466 215 (34.6%)	218 604 (38.0%)	422 150 (44.3%)	9 580 (7.2%)	23 122 (5.3%)	5764 (7.4%)	16 478 (5.4%)
50–59	134 708 (13.1%)	256 327 (19.0%)	82 701 (14.4%)	178 910 (18.8%)	25 101 (18.9%)	105 630 (24.4%)	24 913 (32.1%)	86 221 (28.5%)
60–69	31 162 (3.0%)	51 694 (3.8%)	25 152 (4.4%)	45 613 (4.8%)	34 925 (26.2%)	148 032 (34.2%)	21 015 (27.1%)	95 064 (31.4%)
70–79	9099 (0.88%)	11 518 (0.86%)	7129 (1.2%)	9708 (1.0%)	18 087 (13.6%)	74 463 (17.2%)	9418 (12.1%)	64 334 (21.3%)
80 or more	2941 (0.29%)	2281 (0.17%)	2172 (0.38%)	1824 (0.19%)	8579 (6.4%)	19 846 (4.6%)	3926 (5.1%)	17 977 (5.9%)
Missing data	103	139	63	126	17	19	4	4
Indigenous status								
Indigenous	7326 (1.7%)	20 245 (1.5%)	3927 (1.5%)	12 228 (1.3%)	975 (1.09%)	4551 (1.1%)	656 (1.2%)	3019 (1.0%)
Non-Indigenous	413 593 (98.3%)	1 303 080 (98.5%)	260 948 (98.5%)	910 202 (98. 7%)	88 630 (98.9%)	416 314 (98.9%)	55 538 (98.8%)	284 443 (99.0%)
Missing data	607 755	22 983	311 216	31 274	43 516	12 562	21 417	15 082

IQR = interquartile range.

* Proportions exclude missing data.

† Vaxzevria available only to people aged 18 years or older.

Table 2. Any adverse event following COVID-19 vaccination, as reported in the AusVaxSafety day 3 COVID-19 vaccine safety survey, 22 February – 30 August 2021, by vaccine, dose number, and respondent characteristics (next page)

Characteristic	Comirnaty				Vaxzevria			
	Dose 1		Dose 2		Dose 1		Dose 2	
	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)
Any adverse event	483 003/1 346 308 (35.9%)		521 748/953 704 (54.7%)		228 685/433 427 (52.8%)		66 726/302 544 (22.0%)	
Sex								
Men	160 764/565 158 (28.4%)	1	181 950/399 392 (45.6%)	1	93 652/199 643 (46.9%)	1	23 052/136 689 (16.9%)	1
Women	320 712/777 187 (41.3%)	1.73 (1.72–1.74)	338 101/551 535 (61.3%)	1.84 (1.82–1.86)	133 113/230 019 (57.9%)	1.53 (1.51–1.55)	43 174/163 831 (26.4%)	1.64 (1.60–1.67)
Other	782/1700 (46.0%)	1.96 (1.76–2.16)	690/1021 (67.6%)	2.39 (2.06–2.75)	199/285 (69.8%)	1.32 (0.98–1.75)	40/92 (44%)	2.57 (1.61–3.92)
Age group (years)								
16–19*	15 169/53 457 (28.4%)	0.72 (0.71–0.74)	6354/12 039 (52.8%)	0.73 (0.70–0.76)	2104/2 835 (74.2%)	0.74 (0.67–0.81)	103/259 (39.8%)	1.01 (0.76–1.32)
20–29	67 054/187 231 (35.8%)	1	60 933/101 177 (60.2%)	1	21 968/27 402 (80.2%)	1	3966/9212 (43.0%)	1
30–39	119 600/317 446 (37.7%)	1.11 (1.10–1.12)	105 951/182 157 (58.2%)	0.98 (0.96–0.99)	23 733/32 078 (74.0%)	0.72 (0.69–0.75)	5296/12 995 (40.8%)	0.94 (0.88–0.99)
40–49	174 767/466 215 (37.5%)	1.10 (1.09–1.12)	235 463/422 150 (55.8%)	0.90 (0.89–0.92)	15 857/23 122 (68.6%)	0.51 (0.49–0.53)	6199/16 478 (37.6%)	0.81 (0.77–0.86)
50–59	87 994/256 327 (34.3%)	0.94 (0.93–0.95)	89 607/178 910 (50.1%)	0.70 (0.68–0.71)	63 688/105 630 (60.3%)	0.38 (0.37–0.40)	23 634/86 221 (27.4%)	0.56 (0.54–0.59)
60–69	15 254/51 694 (29.5%)	0.67 (0.66–0.69)	19 701/45 613 (43.2%)	0.48 (0.47–0.49)	71 159/148 032 (48.1%)	0.23 (0.23–0.24)	18 430/95 064 (19.4%)	0.36 (0.35–0.38)
70–79	2643/11 518 (23.0%)	0.47 (0.45–0.49)	3219/9708 (33.2%)	0.31 (0.30–0.33)	25 463/74 463 (34.2%)	0.14 (0.13–0.14)	7524/64 334 (11.7%)	0.23 (0.22–0.24)
80 or more	465/2281 (20.4%)	0.41 (0.37–0.45)	447/1824 (24.5%)	0.20 (0.18–0.22)	4704/19 846 (23.7%)	0.08 (0.08–0.09)	1573/17 977 (8.8%)	0.17 (0.16–0.18)
Indigenous status								
Indigenous	7443/20 245 (36.8%)	0.98 (0.95–1.01)	6447/12 228 (52.7%)	0.84 (0.81–0.87)	2230/4 551 (49.0%)	0.71 (0.67–0.75)	625/3019 (20.7%)	0.80 (0.73–0.88)
Non-Indigenous	467 856/1 303 080 (35.9%)	1	498 268/910 202 (54.7%)	1	219 938/416 314 (52.8%)	1	62 624/284 443 (22.0%)	1
Clinic type								

Characteristic	Comirnaty				Vaxzevria			
	Dose 1		Dose 2		Dose 1		Dose 2	
	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)
General practice (opt-out)	18 030/57 032 (31.6%)	1	13 893/28 361 (49.0%)	1	87 262/191 734 (45.5%)	1	19 218/129 120 (14.9%)	1
ACCHO (opt-in)	996/2301 (43.3%)	1.60 (1.46–1.75)	752/1244 (60.4%)	1.76 (1.55–2.00)	257/443 (58.0%)	1.26 (1.04–1.51)	94/345 (27.2%)	1.45 (1.13–1.82)
ACCHO (opt-out)	52/182 (28.6%)	0.87 (0.61–1.21)	40/95 (42.1%)	0.87 (0.53–1.34)	22/50 (44.0%)	0.88 (0.47–1.50)	10/52 (19.2%)	1.29 (0.60–2.34)
Vaccination hub (opt-in)	92 855/213 607 (43.5%)	1.65 (1.59–1.72)	95 524/155 040 (61.6%)	1.82 (1.72–1.92)	22 411/35 806 (62.6%)	1.22 (1.19–1.26)	5062/14 375 (35.2%)	1.99 (1.89–2.08)
Vaccination hub (opt-in)	371 070/1 073 186 (34.6%)	1.16 (1.14–1.19)	411 539/768 964 (53.5%)	1.15 (1.12–1.18)	118 733/205 394 (57.8%)	1.13 (1.11–1.15)	42 342/158 652 (26.7%)	1.42 (1.38–1.46)
Jurisdiction								
New South Wales	186 874/532 713 (35.1%)	1	204 552/376 030 (54.4%)	1	64 339/118 403 (54.3%)	1	15 321/70 035 (21.9%)	1
Australian Capital Territory	20 778/44 942 (46.2%)	1.08 (1.03–1.13)	23 676/36 335 (65.2%)	0.97 (0.91–1.03)	10 904/18 765 (58.1%)	1.23 (1.19–1.27)	2511/10 543 (23.8%)	1.21 (1.14–1.27)
Northern Territory	5705/13 640 (41.8%)	0.91 (0.86–0.96)	5927/9948 (59.6%)	0.75 (0.70–0.81)	1634/3182 (51.4%)	0.93 (0.86–1.00)	465/2086 (22.3%)	0.83 (0.74–0.93)
Queensland	52 052/126 560 (41.1%)	0.90 (0.86–0.96)	50 458/85 799 (58.8%)	0.76 (0.71–0.81)	22 990/44 128 (52.1%)	0.93 (0.91–0.96)	5142/25 731 (20.0%)	0.89 (0.86–0.93)
South Australia	12 962/28 701 (45.2%)	1.02 (0.97–1.07)	11 620/18 001 (64.6%)	0.90 (0.85–0.97)	10 386/19 940 (52.1%)	0.98 (0.95–1.02)	1974/10 093 (19.6%)	0.88 (0.83–0.93)
Tasmania	6149/14 287 (43.0%)	0.98 (0.93–1.03)	7003/11 523 (60.8%)	0.82 (0.76–0.88)	3316/7506 (44.2%)	0.87 (0.83–0.91)	1160/6244 (18.6%)	0.95 (0.88–1.02)
Victoria	125 144/365 947 (34.2%)	0.91 (0.90–0.92)	159 659/293 358 (54.4%)	0.92 (0.91–0.93)	77 069/144 644 (53.3%)	0.90 (0.88–0.91)	29 045/120 111 (24.2%)	1.02 (0.99–1.05)
Western Australia	73 339/219 518 (33.4%)	0.91 (0.90–0.92)	58 853/122 710 (48.0%)	0.75 (0.74–0.77)	38 047/76 859 (49.5%)	0.91 (0.89–0.93)	11 108/57 701 (19.2%)	0.84 (0.82–0.87)
Anaphylaxis history								
No	468 196/1 314 436 (35.6%)	1	507 770/932 392 (54.5%)	1	222 335/422 990 (52.6%)	1	64 637/295 962 (21.8%)	1
Yes	14 807/31 872 (46.5%)	1.40 (1.36–1.43)	13 978/21 312 (65.6%)	1.42 (1.38–1.47)	6350/10 437 (60.8%)	1.28 (1.23–1.34)	2089/6582 (31.7%)	1.45 (1.36–1.53)

Characteristic	Comirnaty				Vaxzevria			
	Dose 1		Dose 2		Dose 1		Dose 2	
	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)
Underlying medical condition								
None	417 140/1 202 780 (34.7%)	1	457 386/850 183 (53.8%)	1	188 118/352 539 (53.4%)	1	52 302/244 003 (21.4%)	1
Any	65 863/143 528 (45.9%)	—	64 362/103 521 (62.2%)	—	40 567/80 888 (50.2%)	—	14 424/58 541 (24.6%)	—
Coronary heart disease or failure	3541/9832 (36.0%)	1.36 (1.30–1.42)	3591/7228 (49.7%)	1.28 (1.22–1.34)	6586/15 624 (42.2%)	1.18 (1.14–1.22)	2147/12 042 (17.8%)	1.51 (1.43–1.58)
Poorly controlled hypertension	3646/8804 (41.4%)	1.48 (1.42–1.55)	3289/5756 (57.1%)	1.39 (1.32–1.47)	3324/7377 (45.1%)	1.10 (1.05–1.16)	1047/4963 (21.1%)	1.55 (1.44–1.66)
Diabetes	11 650/30 834 (37.8%)	1.23 (1.20–1.27)	12 082/23 108 (52.3%)	1.09 (1.06–1.12)	9814/22 778 (43.1%)	0.94 (0.92–0.97)	3235/17 089 (18.9%)	1.21 (1.16–1.27)
Chronic lung disease	3094/6902 (44.8%)	1.56 (1.48–1.64)	2761/4522 (61.1%)	1.43 (1.34–1.53)	3376/7572 (44.6%)	1.09 (1.04–1.15)	1287/6033 (21.3%)	1.56 (1.46–1.67)
Obesity	6552/12 935 (50.6%)	1.75 (1.68–1.81)	5929/8859 (66.9%)	1.59 (1.52–1.67)	3815/7198 (53.0%)	1.15 (1.09–1.21)	1 379/4863 (28.4%)	1.69 (1.58–1.81)
Chronic kidney failure	657/1932 (34.0%)	1.11 (1.01–1.23)	688/1431 (48.1%)	0.97 (0.87–1.08)	701/1914 (36.6%)	0.90 (0.81–0.99)	265/1558 (17.0%)	1.32 (1.14–1.52)
Chronic liver disease	1035/2365 (43.8%)	1.56 (1.43–1.69)	987/1678 (58.8%)	1.36 (1.23–1.51)	494/1044 (47.3%)	1.04 (0.91–1.18)	183/753 (24.3%)	1.54 (1.28–1.83)
Non-haematological malignancies diagnosed in past 12 months	1336/3498 (38.2%)	1.24 (1.15–1.33)	1366/2424 (56.4%)	.25 (1.15–1.37)	1347/3485 (38.6%)	0.92 (0.85–0.99)	467/2634 (17.7%)	1.29 (1.15–1.43)
Haematological malignancies diagnosed in past five years	613/1696 (36.1%)	1.31 (1.18–1.45)	642/1271 (50.5%)	1.12 (0.99–1.26)	706/1809 (39.0%)	0.91 (0.82–1.01)	332/1254 (26.5%)	2.33 (2.03–2.66)
Currently receiving chemotherapy or radiotherapy	398/1104 (36.0%)	1.10 (0.97–1.26)	384/693 (55.4%)	1.26 (1.07–1.47)	377/1040 (36.2%)	0.90 (0.70–0.91)	152/781 (19.5%)	1.40 (1.14–1.68)
Organ transplant recipient on immune suppressive therapy	434/1147 (37.8%)	1.20 (1.06–1.36)	385/824 (46.7%)	0.80 (0.69–0.93)	243/599 (40.6%)	0.75 (0.62–0.90)	122/501 (24.4%)	1.47 (1.17–1.81)

Characteristic	Comirnaty				Vaxzevria			
	Dose 1		Dose 2		Dose 1		Dose 2	
	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)	Any adverse event	aOR (95% CrI)
Bone marrow transplant recipient in past two years	48/128 (37.5%)	1.37 (0.91–1.95)	45/86 (52.3%)	1.17 (0.70–1.83)	30/80 (37.5%)	0.78 (0.47–1.23)	13/53 (24.5%)	1.43 (0.63–2.72)
Neurological condition	2571/5887 (43.7%)	1.43 (1.35–1.51)	2428/4048 (60.0%)	1.28 (1.20–1.37)	1451/3555 (40.8%)	0.97 (0.90–1.04)	565/2678 (21.1%)	1.50 (1.35–1.66)
Chronic inflammatory conditions	12 155/25 366 (47.9%)	1.57 (1.53–1.61)	11 978/18 792 (63.7%)	1.39 (1.35–1.44)	5760/11 388 (50.6%)	1.05 (1.01–1.10)	2481/8432 (29.4%)	1.75 (1.65–1.84)
Primary or acquired immunodeficiency	1261/2700 (46.7%)	1.73 (1.60–1.87)	1198/2028 (59.1%)	1.40 (1.27–1.53)	517/1008 (51.3%)	1.04 (0.91–1.18)	237/713 (33.2%)	2.24 (1.89–2.63)

ACCHO=Aboriginal Community Controlled Health Organisation; aOR = adjusted odds ratio; CrI = credible interval.

* Vaxzevria available only to people aged 18 years or older.